358 related articles for article (PubMed ID: 35731915)
1. Emerging medicines to improve the basic defect in cystic fibrosis.
Fajac I; Sermet-Gaudelus I
Expert Opin Emerg Drugs; 2022 Sep; 27(3):229-239. PubMed ID: 35731915
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators.
Fajac I; Sermet-Gaudelus I
Curr Opin Pulm Med; 2021 Nov; 27(6):567-574. PubMed ID: 34494979
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators.
Fajac I; Sermet I
Cells; 2021 Oct; 10(10):. PubMed ID: 34685773
[TBL] [Abstract][Full Text] [Related]
4. An update on new and emerging therapies for cystic fibrosis.
Hudock KM; Clancy JP
Expert Opin Emerg Drugs; 2017 Dec; 22(4):331-346. PubMed ID: 29264936
[TBL] [Abstract][Full Text] [Related]
5. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
6. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
[TBL] [Abstract][Full Text] [Related]
7. Discovery of CFTR modulators for the treatment of cystic fibrosis.
Lopes-Pacheco M; Pedemonte N; Veit G
Expert Opin Drug Discov; 2021 Aug; 16(8):897-913. PubMed ID: 33823716
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of cystic fibrosis treatment.
Carter SC; McKone EF
Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
[TBL] [Abstract][Full Text] [Related]
9. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
Cuyx S; De Boeck K
Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
[TBL] [Abstract][Full Text] [Related]
10. CFTR Modulators: From Mechanism to Targeted Therapeutics.
Yeh HI; Sutcliffe KJ; Sheppard DN; Hwang TC
Handb Exp Pharmacol; 2024; 283():219-247. PubMed ID: 35972584
[TBL] [Abstract][Full Text] [Related]
11. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.
Ensinck MM; Carlon MS
Cells; 2022 Jun; 11(12):. PubMed ID: 35740997
[TBL] [Abstract][Full Text] [Related]
12. A foetus with cystic fibrosis - To treat or not to treat?
Padmakumar N; Khan HS
Respir Med Res; 2023 Jun; 83():101006. PubMed ID: 37037055
[TBL] [Abstract][Full Text] [Related]
13. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
Solomon GM; Marshall SG; Ramsey BW; Rowe SM
Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
[TBL] [Abstract][Full Text] [Related]
14. New Therapies to Correct the Cystic Fibrosis Basic Defect.
Bergeron C; Cantin AM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201249
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule drugs for cystic fibrosis: Where are we now?
Laselva O; Guerra L; Castellani S; Favia M; Di Gioia S; Conese M
Pulm Pharmacol Ther; 2022 Feb; 72():102098. PubMed ID: 34793977
[TBL] [Abstract][Full Text] [Related]
16. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
Derichs N
Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
[TBL] [Abstract][Full Text] [Related]
17. New treatments targeting the basic defects in cystic fibrosis.
Fajac I; Wainwright CE
Presse Med; 2017 Jun; 46(6 Pt 2):e165-e175. PubMed ID: 28554723
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.
Mutyam V; Du M; Xue X; Keeling KM; White EL; Bostwick JR; Rasmussen L; Liu B; Mazur M; Hong JS; Falk Libby E; Liang F; Shang H; Mense M; Suto MJ; Bedwell DM; Rowe SM
Am J Respir Crit Care Med; 2016 Nov; 194(9):1092-1103. PubMed ID: 27104944
[TBL] [Abstract][Full Text] [Related]
19. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
Mayer-Hamblett N; Boyle M; VanDevanter D
Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
[TBL] [Abstract][Full Text] [Related]
20. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
Bell SC; De Boeck K; Amaral MD
Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
